NICE deems Bristol-Myers' Opdivo too pricey for lung cancer

Opdivo bottle

England’s cost-effectiveness watchdogs are influential arbiters in the drug-reimbursement world. Other countries often look to the National Institute for Health and Care Excellence when making their own decisions about which drugs to cover.

They’re also notoriously tough on expensive cancer drugs.

Consider NICE’s latest draft guidance: The agency says it’s not inclined to cover Opdivo, the Bristol-Myers Squibb immuno-oncology treatment, for non-small cell lung cancer. The med has some solid effectiveness data backing its use, including overall survival results that reportedly impressed the FDA into approving it ahead of schedule.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Indeed, in its appraisal documents, NICE acknowledged that Opdivo was better at extending patients’ lives than standard treatment with docetaxel, and that Opdivo came with fewer side effects than chemotherapy treatments. The agency said that treatment options for NSCLC patients who’ve failed on prior therapy are few.

Bristol-Myers also offered a cost-sharing deal: England’s National Health Service would pay for 26 weeks of treatment, or about £31,000 ($45,000). The next 26 weeks, if needed, would be covered by the company.

Still, NICE considered Opdivo too expensive for the benefits it confers. When its cost is calculated alongside its survival advantage over docetaxel, Opdivo cost £91,100 per quality-adjusted life year (QALY), which is a common measure of cost-effectiveness, the agency said.

The upshot? Opdivo is a “clinically-effective treatment option” for previously treated patients with NSCLC, but “the committee did not recommend nivolumab as a cost-effective use of NHS resources.”

This is a draft guidance, and NICE will be collecting comments on its assessment through June 3. NICE has recommended Opdivo for advanced melanoma. Its head-to-head competitor, Merck & Co.’s Keytruda, is also recommended for melanoma, and has not yet been assessed by NICE in lung cancer.

- see the NICE document

Related Articles:
U.K.'s NICE says yes to Opdivo for advanced skin cancer
U.K. cost watchdog gives one-two punch to Roche's Kadcyla and BMS' Opdivo
U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer
U.K. cost watchdog gives second thumbs-up in a week to Merck's Keytruda for skin cancer
BMS' Opdivo produces 5-year survival rate for a third of advanced melanoma patients
Merck's Keytruda lines up its survival data for stepped-up battle with BMS' Opdivo

Suggested Articles

Several Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company's overall performance.

J&J has received its fair share of barbs Oklahoma's bench trial. Whether it'll be held responsible for the state's opioid crisis is now up…

J&J's pharma unit is still on the upswing, thanks to newer meds like Stelara, but execs had to explain disappointing numbers from two blockbusters.